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A BST R AC T   
 
Aim: To investigate the therapeutic effects of Saccharomyces boulardii (S. boulardii) and detect 
blood and tissue penetrations of S. boulardii and Shigella sonnei (S. sonnei) in immunosuppressed 
rats infected with S. sonnei. 
Methods: Forty rats were divided into four groups: Group A (immunosuppressed, not-treated); Group 
B (immunosuppressed, treated with S. boulardii); Group C (immunosuppressed, infected with S. 
sonnei, treated with S. boulardii); Group D (immunosuppressed, infected with S. sonnei). After taking 
samples for blood cultures, the rats were sacrificed. The large bowel, liver, spleen and mesenteric 
lymph nodes (MLN) were removed for microbiological examination.  
Results: S. boulardii in group B and S. sonnei in group D were isolated from blood in some rats. 
Statistical analysis of our data, showed that the numbers of translocated colonies in the liver and 
spleen were relatively higher for S. boulardii in Group B and for S. sonnei in Group D, without 
reaching levels of statistical significance. For MLN, colony counts in Group B was higher than Group 
C and A showing statistical significance. 
Conclusion: The administration of S. boulardii showed promising results for the therapy of S. sonnei 
infection in immunosuppressed rats, but therapeutic usage of S. boulardii should be carefully assessed 
by taking into consideration the risk it poses versus potential benefits in risk groups. 
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Introduction 
Intestinal infections due to Shigella spp. are 
worldwide endemic but it mainly occurs in 
developing countries. Four species of Shigella 
(S); S. dysenteriae, S. flexneri, S. boydii and S. 
sonnei are the causative agents of shigellosis. 
Nearly two-thirds of the infections are caused 
by S. flexneri in low and middle-income 
countries.  
S. sonnei is the leading species in high-income 
countries and the second most common species 
in low and middle-income countries. 
Immunodeficiencies lead to more severe 
clinical manifestations of Shigella infection 
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including persistent or recurrent intestinal 
disease and bacteriemia [1]. Antimicrobial 
agents used as effective options in the treatment 
of shigellosis became limited due to global drug 
resistance [2]. 
Saccharomyces boulardii (S. boulardii) is a 
non-pathogenic yeast used in many countries in 
the treatment of non-specific diarrhea and in 
cases of gut flora impairment. Several 
mechanisms such as fungal antagonism, 
diminution of the pathogenic effects of bacterial 
toxins, stimulation of intestinal immune 
defenses and increased intestinal 
disaccharidase activity can possibly explain the 
actions of S. boulardii in diarrhea. The activity 
of S. boulardii has been extensively studied in 
the contexts of gastroenteritis and antibiotic-
associated diarrhea. The good tolerability of 
this yeast was shown and no serious adverse 
reactions have been reported despite a very 
slight potential risk of blood penetration of S. 
boulardii in immunodeficient individuals [3]. 
This study was conducted with the aim of 
investigating the therapeutic effects of S. 
boulardii in immunosuppressed rats infected 
with S. sonnei and detecting the presence of 
translocations of S. boulardii and S. sonnei in 
vulnerable hosts. 
 
Materials and methods 
These experiments were performed with the 
approval of the Ethics Committee of Duzce 
University School of Medicine (Decision no: 
100-019). The animals which were used in the 
study were provided by Duzce University. The 
procedures were conducted according to 
routine animal care guidelines, and all 
experimental procedures complied with the 
Guide for the Care and Use of Laboratory 
Animals (1996). 
In this study, forty male Wistar albino rats 
weighing 200±20 g were divided into four 
groups of 10 animals each: Group A 
(immunosuppressed, not treated), Group B 
(immunosuppressed, treated with S. boulardii), 
Group C (immunosuppressed, infected with S. 
sonnei, treated with S. boulardii) and Group D 
(immunosuppressed, infected with S. sonnei). 
All rats were housed individually in stainless 
steel cages in an animal room at 200 C with a 
12-hour light-dark cycle. All the rats were fed 
with a laboratory pellet diet and were allowed 
to have free access to water during the course 
of the experiments. Rats were decontaminated 
from antibiotics for 4 days by adding 2 mg/ml 
of streptomycin sulphate (Sigma, St. Louis, 
MO, USA) and 1500 units/ml penicillin-G 
(Sigma) to their water, which was prepared 
daily. Reduction of the gastrointestinal flora 
was confirmed by microscopic examination of 
Gram stained smears of fecal pellets and with 
aerobic cultures of feces for Gram-negative 
enteric bacteria. 
The animals in all groups were given 
cyclophosphamide (Baxter Oncology, 
Germany) intraperitoneally at a dose of 
200mg/kg. Group A was the 
immunosuppressed rats with no infection. On 
the fourth day after immunosuppression, 
Groups C and D were inoculated with 0.1 ml of 
S. sonnei containing 9x108  viable cells by 
gavage route after having cultures of the 
bacteria in Brain Heart Infusion broth (HiMedia 
Laboratories, India) for 12 hours [4]. On the 
third day after the inoculation, S. sonnei was 
isolated from the fecal samples of all rats. 
Lyophilized S. boulardii (Ultra-Levure; 
BIOCODEX Laboratories, Montrouge, France) 
was given to each rat at a single dose of 
10mg/day by gavage route for Groups B and C. 
Group A was given 0.1 ml (same amount as 
other groups) of phosphate buffer saline (PBS), 
as this group was neither inoculated by S. 
boulardii nor by S. sonnei. S. boulardii 
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administration was continued for 10 days for 
group B and for five days for group C. The rats 
were sacrificed under ether inhalation on day 
10. 
Prior to being sacrificed, blood samples (2 ml) 
of rats were collected from inferior vena cava 
and inoculated into the bottles of BACTEC 
system (Becton Dickinson, Ireland). 
After the rats were sacrificed; their large 
bowels, liver, spleen and MLN were removed 
for microbiologic examination. To evaluate the 
translocation by microbiological methods; the 
weights of the liver, spleen and nodes were 
recorded.  
To assess S. boulardii and/or S. sonnei 
quantitatively, tissue pieces were minced with a 
scalpel, diluted by tenfold in 0.9% NaCl and 
homogenized with a handled tissue tearer. 
(Ultra-Turrax T25, BioSpec Products, 
Bartlesville, OK, USA). 
Diluted organ homogenates were transferred on 
Sabouraud dextrose agar (SDA) (HiMedia 
Laboratories, India) and Hektoen Enteric (HE) 
(HiMedia Laboratories, India) agar plates. The 
duration of the cultures were as follows: 7 days 
for blood cultures, 72 hours for SDA and 48 
hours for HE agars at 35oC. Microorganisms 
were identified by conventional methods and 
API 32E (BioMerieux, France) and API CAUX 
(BioMerieux, France) systems. Then, the 
number of colonies per tissue gram (cfu / g) was 
determined.  
The translocation index shows the number of 
microorganisms per gram of tissue and was 
calculated by the following formula [5]:  
(Cfu count x dilution coefficient x 10 x 2) / 
Tissue weight.  
 
Statistical Analysis 
The data was expressed as means ± SD. 
Kruskal-Wallis and Mann-Whitney U tests 
were used to compare the numbers of colonies 
between the groups. The differences were 
considered as being significant at p<0.05.  
 
Results  
The number of colonies of the microorganisms 
isolated from the cultures of MLN, liver and 
spleen specimens and the results of blood 
cultures were determined for each group. 
In Group A, in immunosuppressed rats, blood 
and tissue cultures were negative and no 
translocations were seen. 
In Group B (immunosuppressed, treated-with- 
S. boulardii), the results showed that S. 
boulardii translocated and it systemically 
spread to extraintestinal sites of liver, spleen 
and MLN in some rats. Of 10 rats, one yielded 
positive results in the liver, spleen, MLN and 
blood; one yielded positive results in spleen and 
MLN; one yielded positive results in MLN and 
blood; and, lastly, four rats yielded positive 
results in only the MLN cultures.  The isolated 
organism was S. boulardii from the MLN, liver 
and spleen specimens. S. boulardii was also 
isolated from the blood specimens of two rats 
in which translocations were observed. 
In Group C (immunosuppressed, infected-with-
S.sonnei, treated-with- S. boulardii), neither S. 
boulardii nor S. sonnei was isolated from the 
cultures of MLN, liver, spleen and/or blood 
specimens.  
In Group D (immunosuppressed, infected-with-
S. sonnei), the results of the cultures were as 
follows: one rat yielded positive results in the 
liver, spleen, MLN and blood specimens; one 
yielded positive results in the liver, MLN and 
blood specimens; and one rat yielded positive 
results in MLN for S. sonnei. 
The numbers of translocated colonies are listed 
in Table 1 and are expressed as cfu. The 
numbers of translocated colonies in liver and 
spleen were relatively higher for S. boulardii in 
Group B and higher for S. sonnei in Group D, 
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but the difference was not statistically 
significant (p>0.05). For MLN, colony counts 
in Group B was higher than in Groups C and A, 
which was statistically significant (p=0.005). In 
Group D, colonies of S. sonnei was high, but not 
with statistical significance (p=0.068). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion 
S. boulardii is widely used for clinical 
conditions and predominantly for the 
prevention of diarrhea [6,7]. The effects of S. 
boulardii are related to its inhibitory effects on 
the growth of intestinal microorganisms and to 
the neutralization of toxins, however the 
mechanisms underlying such effects could not 
be fully identified. Furthermore, S. boulardii 
has been shown to increase the activity of brush 
border disaccharidases in human volunteers and 
in patients with congenital sucrase isomaltase 
deficiency. In addition, an enhanced release of 
secretory IgA into the intestinal lumen supports 
the immune system [8]. 
Many studies have been conducted to 
investigate the activity of S. boulardii against 
certain agents, including Giardia intestinalis, 
Rotavirus, Entamoeba histolytica, Helicobacter 
pylori, ETEC, Cryptosporidium parvum as well 
as in the treatment of diarrhea associated with 
HIV [9-11]. S. boulardii has been found to 
show a protective effect in Clostridium difficile  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
associated colitis [12,13]. Studies showed a 
protective effect against Salmonella 
typhimurium and Shigella flexneri in the 
intestinal tracts of conventional or gnotobiotic 
mice [14]. The effects of orogastric 
administration of S. boulardii on the jejunal 
villi was studied by Dias et al. [15] in rats 
infected with Vibrio cholerae and their data 
showed the inhibition of the action of the 
cholera toxin on enterocytes by S. boulardii. 
Sheele et al. [16] showed the efficiency of S. 
boulardii in patients in whom the duration and 
severity of cholera was reduced. Zbinden et al. 
[17] investigated the influence of S. boulardii 
on Salmonella typhimurium and Yersinia 
enterocolitica under in vitro conditions and 
Parameters A (n=10) B (n=10) C (n=10) D (n=10) 
Liver* (cfu/g/10
5
) 0.00 363.60±1149.80 0.00 
  
194. 20±409.41 
  
Spleen **(cfu/g/10
5
) 0.00 1039.10±2360.01 0.00 
  
210.50±666.65 
  
MLN*** (cfu/g/10
5
)  0.00 47273.70±75043.94 0.00 10378.70±17400.4 
Bacteriemia/fungemia 0 2 0 2 
 
n= number of rats. B:  For S. boulardii 
*** (p=0.001) (Kruscal-Wallis test); (p=0.005) groups A-B, B-C (Mann-Whitney U test) 
D: For S. sonnei 
*** (p<0.05) (Kruscal-Wallis test): (p=0.068) groups A-D, C-D (Mann-Whitney U test) 
 
Table 1. Numbers of colonies in the liver, spleen, MLN and blood in the four experimental. 
.groups. 
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their results showed that S. boulardii inhibited 
either the growth of both bacteria or their 
invasion into HeLa cells, so they suggested to 
study these effects in vivo as well. 
In recent years, invasive fungal infections have 
been frequently reported worldwide in parallel 
to with the increase in risky population such as 
patients with chronic or debilitating diseases, 
who receive immunosuppressive drugs broad 
spectrum antibiotics, and parenteral nutrition 
and who were administered central venous 
catheter [18]. 
Microbial translocation is defined as the 
passage of viable microbes from the 
gastrointestinal (GI) tract to extraintestinal 
sites, such as the MLN, spleen, liver, kidneys, 
and blood [19]. Overall, S. boulardii is 
considered to be a safe and well tolerated agent, 
but recently, numerous studies reported 
fungemia after S. boulardii treatment for risk 
groups [17,20-28]. Some studies emphasize the 
importance of blood penetration after S. 
boulardii usage in immunosuppressed 
patients resulting in S. boulardii associated 
fungemia [29,30]. For this reason, the 
therapeutic usage of probiotics should be 
carefully evaluated by taking into consideration 
its risks as well as its potential benefits. 
In a study investigating the ability of orally 
administered viable S. boulardii in inhibiting 
translocation of Candida albicans from the 
gastrointestinal tract in antibiotic-
decontaminated, specific pathogen-free mice, 
orally administered S. boulardii was shown to 
decrease the incidence of Candida albicans 
translocation to the MLN, liver and kidneys 
[19].  
Peret Filho et al. [31] studied the translocation 
and histological alterations in the terminal 
ileum, liver and spleens of immunosuppressed 
mice under S. boulardii treatment. The results 
of this study showed that S. boulardii 
administration decreased the bacterial 
translocation to the liver and spleen in a dose 
dependant manner. Low S. boulardii 
translocation to MLN was observed in some 
animals. In our study, in Group B, translocation 
to MLN was significantly higher (p=0.005). 
The translocation to spleen and liver was also 
high, but the difference was not statistically 
significant (p>0.05). In evaluation of the blood 
cultures, two rats (20%) in Group B developed 
fungemia due to Saccharomyces cerevisiae 
representing the translocation of S. boulardii. 
Comparing our results with Peret et al. [31] our 
findings also support the relative protection 
with S. boulardii in immunosuppressed rats. 
However, reported cases in clinical trials and 
development of fungemia in two 
immunosuppressed rats showed the importance 
of probable fungemia during treatment. 
Shigellosis is currently an important public 
health problem. Shigella bacteriemia is rare but 
associated with a high mortality rate. 
Immunosuppressed patients, malnourished 
children, and elderly people are at risk of 
serious complications and bacteriemia [2,32]. 
In experiments on white mice, S. sonnei strains 
were shown to be capable of penetrating into 
the blood for a short period of time [33]. Over 
the past decades, Shigella strains have 
progressively become resistant to most of the 
widely used antimicrobials [2]. For this reason, 
alternative therapeutic approaches are under 
investigation. In our study, we investigated the 
therapeutic effects of S. boulardii in S. sonnei 
infection, which is the predominant cause of 
Shigellosis in our country and the translocation 
rate of S. sonnei and S. boulardii in 
immunosuppressed hosts. The results of our 
study showed that in some rats in the D group 
S. sonnei cause bacteremia and caused 
translocation in the MLN, liver and spleen. 
These results showed the importance of 
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bacterial translocation in immunosuppressed 
rats. In group C, in which the 
immunosuppressed rats were infected with S. 
sonnei and treated with S. boulardii, no 
translocation and no growth in blood cultures 
was observed.  
 
Conclusion 
Both S. boulardii and S. sonnei caused 
translocation resulting in fungemia/ 
bacteriemia in immunosuppressed rats when 
they were applied individually; but S. boulardii 
administration to S. sonnei infected rats seemed 
to result in the inhibition of translocation and 
bacteriemia. S. boulardii administration is 
found to be effective in the treatment of S. 
sonnei infections in immunosuppressed rats 
under in vivo conditions, but potential risk of 
developing fungemia in risk groups must 
always be considered during the therapeutic use 
of S. boulardii. 
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